{
  "num_tested_probands": 1,
  "num_positive_het_probands": 0,
  "positive_phenotypes": [
    "early developmental delay",
    "motor weakness",
    "intellectual disability",
    "acute liver failure",
    "severe progressive encephalopathy"
  ],
  "num_compound_or_double_hets": 0,
  "explanation": {
    "num_tested_probands": "The text does not provide explicit information on the number of probands tested, which could be inferred from the context as a single individual.",
    "num_positive_het_probands": "The text does not explicitly state whether the subject is a heterozygous carrier or not, despite mentioning that 'the diagnosis of a mitochondrial defect was made' after sodium valproate treatment.",
    "positive_phenotypes": "The text mentions that the subject had early developmental delay, motor weakness, and intellectual disability. It also mentions that she developed acute liver failure and severe progressive encephalopathy after starting sodium valproate treatment.",
    "num_compound_or_double_hets": "The text does not explicitly mention the number of compound or double heterozygotes, but it mentions that 'two known pathogenic variants were detected in WARS2' and that the subject had a 'mosaic pattern was seen in hepatocytes after cytochrome c oxidase staining'. This suggests that the subject may have compound or double heterozygosity, but it is not explicitly stated."
  }
}